A chemically optimized, GalNAc-conjugated siRNA targeting HSD17B13 demonstrates efficacy in a human 3D organoid model of MASH, showcasing an alternative to animal testing

Qin Meng, Xujia Wang, Yuxuan Zhang, Sudeep Pushpakom, Jun Yang, Hui Feng, Mu Wang · 2026

Read A chemically optimized, GalNAc-conjugated siRNA targeting HSD17B13 demonstrates efficacy in a human 3D organoid model of MASH, showcasing an alternative to animal testing by Qin Meng, Xujia Wang, Yuxuan Zhang, Sudeep Pushpakom, Jun Yang, Hui Feng, Mu Wang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0354751.txt.

Description

Qin Meng and colleagues designed a gene-silencing drug candidate for a serious fatty liver disease known as MASH. Animal models predict human responses poorly for this disease, slowing drug development. Their 2026 study paired careful chemical design of small interfering RNA with a human three-dimensional liver organoid model.

The lead molecule carried a sugar tag that steers it to liver cells and chemical tweaks that keep it stable. It survived well in human serum and liver preparations and showed few off-target risks. In the organoid model it lowered fat build-up and scarring signals, matching a drug already in clinical testing. Meng and colleagues offer both a candidate and a testing route that reduces animal use.

Catalog record

CREATORQin Meng, Xujia Wang, Yuxuan Zhang, Sudeep Pushpakom, Jun Yang, Hui Feng, Mu Wang
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE27226
LICENSECC_BY
RIGHTSCC BY
SOURCEPLOS

Source: https://doi.org/10.1371/journal.pone.0354751

Browse the full library · About the Tower of Babel